Wait over for landmark EMA policy on trial data access
This article was originally published in SRA
Executive Summary
Nearly all of the clinical trial data in new drug marketing applications that are submitted to the European Medicines Agency for evaluation after 1 January 2015 will be made available to the public following the drug's approval, the agency's eagerly-awaited final policy on proactive publication of trial data has revealed1-3.
You may also be interested in...
Canada Launches Portal To Proactively Disclose Clinical Data On Approved Devices, Drugs
Following in the footsteps of the European Medicines Agency, Canada has launched a publicly-accessible portal to proactively disclose clinical trial information on approved medical devices and drugs that was hitherto considered confidential.
Canada Launches Portal To Proactively Disclose Clinical Data On Approved Drugs, Devices
Following in the footsteps of the European Medicines Agency, Canada has launched a publicly-accessible portal to proactively disclose clinical trial information on approved drugs and medical devices that was hitherto considered confidential.
EMA Rejects 76% Of Requests To Label Info In Clinical Reports As Commercially Confidential
Most of the proposals by companies to redact commercially confidential information in their clinical study reports under the European Medicines Agency’s policy on proactive publication of clinical trial data have been rejected. Meanwhile, the agency is planning to make improvements to the policy this year.